HomeCompareIRT vs AMGN

IRT vs AMGN: Dividend Comparison 2026

IRT yields 4.59% · AMGN yields 2.77%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMGN wins by $130.9K in total portfolio value· pulled ahead in Year 3
10 years
IRT
IRT
● Live price
4.59%
Share price
$14.81
Annual div
$0.68
5Y div CAGR
10.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.3K
Annual income
$1,914.49
Full IRT calculator →
AMGN
AMGN
● Live price
2.77%
Share price
$349.00
Annual div
$9.66
5Y div CAGR
48.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$164.2K
Annual income
$69,743.86
Full AMGN calculator →

Portfolio growth — IRT vs AMGN

📍 AMGN pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIRTAMGN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IRT + AMGN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IRT pays
AMGN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IRT
Annual income on $10K today (after 15% tax)
$390.28/yr
After 10yr DRIP, annual income (after tax)
$1,627.32/yr
AMGN
Annual income on $10K today (after 15% tax)
$235.27/yr
After 10yr DRIP, annual income (after tax)
$59,282.28/yr
At 15% tax rate, AMGN beats the other by $57,654.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IRT + AMGN for your $10,000?

IRT: 50%AMGN: 50%
100% AMGN50/50100% IRT
Portfolio after 10yr
$98.7K
Annual income
$35,829.17/yr
Blended yield
36.30%
📊

Analyst Conviction Gap

Where Wall Street is split right now

IRT
Analyst Ratings
19
Buy
8
Hold
Consensus: Buy
Price Target
$20.08
+35.6% upside vs current
Range: $18.00 — $22.00
Altman Z
0.7
Piotroski
6/9
AMGN
Analyst Ratings
22
Buy
13
Hold
3
Sell
Consensus: Buy
Price Target
$347.73
-0.4% upside vs current
Range: $185.00 — $432.00
Altman Z
2.3
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IRT buys
0
AMGN buys
0
No recent congressional trades found for IRT or AMGN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIRTAMGN
Forward yield4.59%2.77%
Annual dividend / share$0.68$9.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR10.1%48.6%
Portfolio after 10y$33.3K$164.2K
Annual income after 10y$1,914.49$69,743.86
Total dividends collected$10.7K$133.8K
Payment frequencyquarterlyquarterly
SectorREITHealthcare
Analyst consensusBuyBuy
Analyst price target$20.08$347.73

Year-by-year: IRT vs AMGN ($10,000, DRIP)

YearIRT PortfolioIRT Income/yrAMGN PortfolioAMGN Income/yrGap
1$11,206$505.52$11,111$411.31+$95.00IRT
2$12,573$582.88$12,524$634.70+$49.00IRT
3← crossover$14,126$672.95$14,394$993.52$268.00AMGN
4$15,893$777.98$16,987$1,585.83$1.1KAMGN
5$17,906$900.64$20,776$2,599.19$2.9KAMGN
6$20,203$1,044.12$26,645$4,414.70$6.4KAMGN
7$22,830$1,212.23$36,373$7,863.06$13.5KAMGN
8$25,837$1,409.50$53,826$14,907.12$28.0KAMGN
9$29,287$1,641.41$88,231$30,636.84$58.9KAMGN
10$33,252$1,914.49$164,151$69,743.86$130.9KAMGN

IRT vs AMGN: Complete Analysis 2026

IRTREIT

Independence Realty Trust, Inc. (NYSE: IRT) is a real estate investment trust that owns and operates multifamily apartment properties across non-gateway U.S. markets, including Atlanta, Louisville, Memphis, and Raleigh. IRT's investment strategy is focused on gaining scale within key amenity rich submarkets that offer good school districts, high-quality retail and major employment centers. IRT aims to provide stockholders attractive risk-adjusted returns through diligent portfolio management, strong operational performance, and a consistent return on capital through distributions and capital appreciation.

Full IRT Calculator →

AMGNHealthcare

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Full AMGN Calculator →
📬

Get this IRT vs AMGN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IRT vs SCHDIRT vs JEPIIRT vs OIRT vs KOIRT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.